HB0025 Injection

DRUG2 trials

Sponsors

Shanghai Huaota Biopharmaceutical Co., Ltd.

Conditions

First-line pMMR Endometrial CancerNon Squamous Non-small Cell Lung Cancer

Phase 3

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Not yet recruitingNCT07383116

Shanghai Huaota Biopharmaceutical Co., Ltd.Non Squamous Non-small Cell Lung Cancer

Start: 2026-01-15End: 2028-04-10Target: 500Updated: 2026-02-03

HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer

RecruitingNCT07902999

Shanghai Huaota Biopharmaceutical Co., Ltd.First-line pMMR Endometrial Cancer

Start: 2026-10-20End: 2031-06-26Target: 333Updated: 2026-10-29